Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
Date:4/9/2013

ATLANTA, April 9, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that 2013 first quarter financial results will be released on Tuesday, April 30, 2013.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson , president and chief executive officer of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m.  A replay of the teleconference will be available April 30 through May 7 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415.  The conference number for the replay is 411859.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife website at www.cryolife.com and selecting the heading Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter, can be accessed on the Investor Relations section of the CryoLife website.

About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europa, and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia.  CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  Additional marketing approvals for BioGlue have been granted in several other countries throughout the world.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  In addition, CryoLife and its subsidiary Hemosphere, Inc. market the HeRO® Graft, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community and other select international countries.  CryoLife's BioFoam Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. 

For additional information about the company, visit CryoLife's website: 
http://www.cryolife.com.

Contacts:

CryoLife

D. Ashley Lee

Executive Vice President, Chief Financial Officer

and Chief Operating Officer

Phone: 770-419-3355

The Ruth Group

Nick Laudico / Zack Kubow

646-536-7030 / 7020

nlaudico@theruthgroup.com

zkubow@theruthgroup.com


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
4. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Initiation of Quarterly Cash Dividend
7. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. CryoLife Receives Expanded Indication for BioFoam in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
11. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer market ... of the market globally. The stakeholders of this ... manufacture and commercialization of various mass spectrometer instrument ... to enter this market. This report comprises an ...
(Date:2/21/2017)... , Feb. 21, 2017  Luminex Corporation (NASDAQ: ... directors has authorized the initiation of a quarterly cash dividend ... initial cash dividend will be payable on April 14, 2017 ... on March 24, 2017. The board of ... cash dividend of $0.06 to holders of its common stock, ...
(Date:2/21/2017)... , Feb. 21, 2017  Global health services company ... Dermacell ® for breast reconstruction surgery and ... is an advanced acellular dermal matrix developed by LifeNet ... NVDQ ) "We are ... commercial health-care payers to review the growing base of ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... One of ... despite the medical, mental health, and financial consequences of inaction. On March 3, ... action if they have concerns about their hearing. , Effective treatment in the ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... MRI screening ... to a new study from Germany published online in the journal Radiology . ... that offers better sensitivity than mammography and ultrasound. Currently, guidelines reserve breast MRI screening ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... 213-8818 , Orbita, Inc., a leading provider of innovative software for connected home ... patient engagement and optimizing care journey management for home healthcare. , Built ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... you to stop by for a visit this week at HIMSS 2017 Conference ... executives from around the globe. Sensogram will be featured in the conference’s Connected ...
(Date:2/20/2017)... ... 20, 2017 , ... Chuck E. Cheese’s® and Center for Autism and Related ... Chuck E. Cheese’s locations throughout New England, New York and New Jersey to provide ... the fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. , After ...
Breaking Medicine News(10 mins):